Lupus nephritis (LN) leads to end-stage kidney disease (ESKD) in 10-22% of these patients and is associated with up to a 30% mortality rate at 10 years1,2. Belimumab or a calcineurin inhibitor (CNI) such as voclosporin or tacrolimus may be added as triple therapy. While triple therapy involving belimumab or a CNI appears very promising, data for its long-term benefit are still lacking. The use of triple therapy should be carefully considered based on individual patient characteristics and the relative risk and benefits of these therapies. Second, a post hoc analysis of the ALMS trial favored use of mycophenolate over cyclophosphamide in Hispanic and Black patients10,11.